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A B S T R A C T   
Myotonic Dystrophy type 1 (DM1) is an autosomal dominant condition caused by expansion of the CTG triplet 
repeats within the myotonic dystrophy protein of the kinase (DMPK) gene. The central nervous system is 
involved in the disease, with multiple symptoms including cognitive impairment. A typical feature of DM1 is the 
presence of widespread white matter (WM) lesions, whose total volume is associated with CTG triplet expansion. 
The aim of this study was to characterize the distribution and pathological substrate of these lesions as well as the 
normal appearing WM (NAWM) using quantitative magnetization transfer (qMT) MRI, and comparing data from 
DM1 patients with those from patients with multiple sclerosis (MS). Twenty-eight patients with DM1, 29 patients 
with relapsing-remitting MS, and 15 healthy controls had an MRI scan, including conventional and qMT imaging. 
The average pool size ratio (F), a proxy of myelination, was computed within lesions and NAWM for every 
participant. The lesion masks were warped into MNI space and lesion probability maps were obtained for each 
patient group. The lesion distribution, total lesion load and the tissue-specific mean F were compared between 
groups. The supratentorial distribution of lesions was similar in the 2 patient groups, although mean lesion 
volume was higher in MS than DM1. DM1 presented higher prevalence of anterior temporal lobe lesions, but 
none in the cerebellum and brainstem. Significantly reduced F values were found within DM1 lesions, suggesting 
a loss of myelin density. While F was reduced in the NAWM of MS patients, it did not differ between DM1 and 
controls. Our results provide further evidence for a need to compare histology and imaging using new MRI 
techniques in DM1 patients, in order to further our understanding of the underlying disease process contributing 
to WM disease.   
1. Introduction 
Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder 
caused by an expansion of the trinucleotide CTG repeat motif. Found on 
chromosome 19, the repeat motif is in the 3′UTR of the DMPK gene, 
located at point 13.3 (Brook et al., 1992; Fu et al., 1993; Mahadevan 
et al., 1993). DM1 affects at least 1 in 8000 people worldwide and is the 
most common form of neuromuscular disorder with clinical onset in 
adulthood (Emery, 1991; Meola & Cardani, 2015). DM1 is a multisystem 
disorder affecting the heart, both smooth and skeletal muscle, the eyes, 
endocrine system, central and peripheral nervous system (Romeo, 2012; 
Schara and Schoser, 2014; Turner & Hilton-Jones, 2014; Ashizawa et al., 
2018). Post-mortem examinations of the brain of people with DM1 have 
highlighted the presence of nuclear RNA foci (i.e., CTG repeats) (Jiang 
et al., 2004), and of neurofibrillary tangles, leading to the disease being 
considered a tauopathy (Yoshimura et al., 1990; Vermersch et al., 1996). 
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Although adult onset DM1 patients typically present with preserved 
global cognition at formal testing (Di Costanzo et al., 2002; Minnerop 
et al., 2011; Serra et al., 2015), when examined more closely, detailed 
cognitive testing has revealed executive and memory dysfunctions 
(Meola et al., 2003; Modoni et al., 2004; Weber et al., 2010) as well as 
dysfunction of social cognition (Serra et al., 2016, 2020), and patho-
logical personality traits (Serra et al., 2014), partially explained by 
altered functional connectivity (Serra et al., 2014, 2016) and reduced 
regional cortical thickness (Serra et al., 2020). 
Imaging of the brains of those affected by DM1 demonstrates struc-
tural damage in both the grey and white matter, but predominantly 
white matter. Magnetic resonance imaging (MRI) studies described the 
presence of ventricular dilatation and periventricular hyperintensities 
(Glantz et al., 1988; Hund et al., 1997; Di Costanzo et al., 2002; Min-
nerop et al., 2011; Caso et al., 2014), resembling lesions detected in 
other conditions such as multiple sclerosis (MS) (Damian et al., 1994), 
Lyme disease (Fernandez et al., 1990), and coeliac disease (Kieslich 
et al., 2001). Other common findings include cerebral atrophy (Min-
nerop et al., 2011; Serra et al., 2015), and enlarged Virchow-Robinson 
spaces (Di Costanzo et al., 2001). Interestingly, the white matter 
lesion load, regional grey matter volumes, and white matter micro-
structure were all reported to correlate with patient CTG triplet expan-
sion (Serra et al., 2015; Zanigni et al., 2016; van der Plas, et al., 2019). 
Using conventional MRI, white matter T2-hyperintense lesions in the 
anterotemporal and temporopolar regions have been repeatedly re-
ported by studies as areas of typical change in DM1 patients (Huber 
et al., 1989; Miaux et al., 1997; Abe et al., 1998; Ogata et al., 1998; Di 
Costanzo et al., 2001; Zanigni et al., 2016). Anterior temporal lobe le-
sions differ to other lobar lesions seen in DM1, as they appear to involve 
the arcuate fibres, a feature not seen in lobar lesions. The MRI pattern of 
distribution, asymmetry of white matter lesions, involvement and 
sparing of specific structures is thought to be specific to DM1 (Di Cos-
tanzo et al., 2001), although other genetic disorders, such as cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy (CADASIL) and cerebral autosomal recessive arte-
riopathy with subcortical infarcts and leukoencephalopathy (CARASIL) 
are characterised by T2-weighted hyperintensities, which, particularly 
at the onset of the disease, tend to localise to the anterior temporal lobes 
(Liem et al., 2008; Kim et al., 2018). Whether the origin of this particular 
class of lesions differs from that of the others in DM1 remains to be 
determined. In addition to macroscopic lesions, advanced MRI tech-
niques, such as diffusion tensor imaging, provided evidence for subtle 
white matter changes throughout the DM1 brain (Minnerop et al., 2011; 
Serra et al., 2015). 
The substrate of macroscopic lesions and microscopic damage in 
DM1 remains unknown, although axonal loss and demyelination have 
been reported to occur, together with gliosis (Mondelli et al., 1993; 
Vielhaber et al., 2006). Tackling the origin of the widespread brain 
damage observed in DM1 and its link with the severity of the genetic 
load (Serra et al., 2015), is paramount in order to understand the 
pathogenesis of central nervous system symptoms in DM1 and develop 
appropriate interventions. Although a detailed answer to these questions 
can only be achieved with histopathology, quantitative MRI provides a 
useful tool for investigating lesion characteristics in vivo. The purpose of 
the current study was thus to compare the lesion distribution, and its 
substrate (as assessed by quantitative MRI) with another condition 
characterised by spatially disseminated lesions with mixed pathology, 
namely MS. MS is a chronic inflammatory disorder of the central ner-
vous system characterised by focal lesions, pathologically explained by a 
variable combination of demyelination, inflammation, axonal damage 
and gliosis (Filippi et al., 2001; Kutzelnigg et al., 2005; Frischer et al., 
2009; Popescu and Lucchinetti, 2012; Spanò et al., 2018). Microscopic 
tissue abnormalities are known to occur outside macroscopic lesions, in 
the so-called normal-appearing white matter (NAWM) since very early 
clinical stages (Raz et al., 2010). The rationale for this comparison was 
to use MS as a pathological model, against which to compare DM1. One 
of the reasons for choosing MS, is that it has been studied extensively 
using quantitative MRI techniques, including diffusion MRI and 
magnetization transfer (MT) MRI. MT imaging exploits the interaction 
between those protons embedded in macromolecular structures (pro-
teins and lipids) and those in free water to indirectly measure the density 
of the former protons (Wolff and Balaban, 1989). This allows an indirect 
quantification of the myelin content, given the assumption that myelin is 
the predominant macromolecule in the central nervous system (Heath 
et al., 2018). The most commonly used approach to quantify the MT 
effects is the so called MTR or MT-ratio, which is computed as a per-
centage difference between 2 images, one using off-resonance saturation 
(which sensitizes only macromolecules) and one without (Helms et al., 
2008). Pathological changes appear to reduce the density of macro-
molecules and their exchange of magnetization with the free protons, 
thus causing a reduction of the MT ratio (Wolff and Balaban, 1989). The 
MTR, however, is a simplistic approach, highly dependent on the 
acquisition parameters, and with limited sensitivity. In order to over-
come some of these limitations, more complex analytical models have 
been developed to provide a truly ‘quantitative’ estimation of myelin in 
the examined image (Henkelman et al., 1993). Quantitative magneti-
zation transfer (qMT) uses multiple off-resonance frequencies and 
radiofrequency amplitudes to fit an analytical model of the signal, thus 
enabling the estimation of the pool size ratio, or F. The use of F as a 
proxy for myelin density has been validated in MS using post-mortem 
samples (Schmierer et al., 2007) and animal models of demyelination 
and remyelination (Turati et al., 2015). 
Against this background, we set out to compare the myelin density 
(by means of F) in the brain of patients with DM1 to healthy controls and 
to patients with MS as a prototypical disorder of myelin. We first char-
acterised the spatial distribution of lesions, and then quantified the qMT 
parameters inside and outside macroscopic lesions. Finally, we isolated 
temporal lobe lesions in patients with DM1, with the aim to test whether 
their qMT parameters differ from those computed in the lesions detected 
in the rest of the brain. Based on the existing literature, we expected 
DM1 patients to have more white matter lesions than healthy controls, 
with evidence of demyelination (Abe et al., 1994; Mizukami et al., 
1999). However, we hypothesised that the extent of demyelination 
would be lower in DM1 than MS. Finally, while the anterior temporal 
pole might be involved in progressive forms of MS, we did not expect 
anterior temporal lesions to be a prominent feature of patients with 
relapsing remitting MS, included in this study. Therefore, we postulated 
that anteroior temporal lesions would be detecetd in DM1 only, and 
would have different characteristics than other lesions. 
2. Methods 
2.1. Participants 
We recruited 28 patients (M/F = 14/14; mean age: 42, standard 
deviation: 12.1 years) with a molecular diagnosis of DM1 from the 
Neuromuscular and Neurological Rare Diseases Center at San Camillo 
Forlanini Hospital (Rome, Italy) and the Institute of Neurology at the 
Catholic University of Rome (Rome, Italy). A subsample of this cohort 
also participated in an independent study (Serra et al., 2015) but their 
qMT data have not been reported elsewhere. The genetic and clinical 
characteristics of DM1 patients are summarized in Table 1. Twenty-nine 
patients (M/F = 11/18; mean age: 35, standard deviation: 7.64 years) 
with a clinically definite diagnosis of relapsing remitting MS, as defined 
by 2001 McDonald criteria (McDonald et al., 2001) were recruited as the 
MS control group, from the specialist MS outpatient clinic at IRCCS 
Santa Lucia Foundation, Rome, Italy. All patients had a diagnosis of 
relapsing-remitting MS, and those who had any relapse or cortico- 
steroid treatment over the 3 months preceding MR acquisition were 
excluded. DM1 participants had assessment of CTG expansion size 
within the DMPK gene, and they were classified according to the In-
ternational Myotonic Dystrophy Consortium nomenclature (IDMC, 
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2000). Fifteen healthy controls (M/F = 7/8; mean age: 33, standard 
deviation: 8.4 years) were recruited through classified advertisements. 
This study received ethical approval from the ethical committee of the 
IRCCS Santa Lucia Foundation, Rome, Italy. Written informed consent 
was obtained from all participants before study initiation. 
2.2. Genetic assessment 
Blood samples were taken from DM1 patients to detect expanded 
alleles. As previously described (Serra et al., 2015), the analysis of 
normal and proto-mutated alleles was done using “touch down” PCR on 
DNA extracted from peripheral blood leucocytes (PBL). This required 50 
pg of PBL-DNA being amplified in a 20 μl volume with fluorescent 
labelled primer 101 and primer 102. Eight rounds of reactions were 
cycled at 94 ◦C-30”, 68 ◦C-30” (− 1 ◦C per cycle) and 72 ◦C-30”, followed 
by 30 rounds at 94 ◦C-30”, 60 ◦C- and 72 ◦C -30”. Abi-Prism 310 Genetic 
Analyzer was then used to analyse PCR products. Determination of 
expanded alleles was performed on 10 pg of PBL DNA, which underwent 
XL-PCR and 1% agarose gel electrophoresis. Southern blotting with 
subsequent hybridization to a 32P radiolabelled (CTG) 7 oligonucleotide 
probe was then used to analyse PCR products followed by detection 
using autoradiography. 
2.3. MRI acquisition 
All patients and healthy controls received an MRI scan, obtained 
using a head-only 3.0 T scanner (Siemens Magnetom Allegra, Siemens 
Medical Solutions, Erlangen, Germany), equipped with a circularly 
polarised transmit–receive coil. The maximum gradient strength is 40 
mTm− 1, with a maximum slew rate of 400 mTm− 1ms− 1. The MRI session 
included for every subject: (1) a dual-echo turbo spin echo (TSE) (TE1 =
12 ms; TE2 = 109 ms; TR = 6190 ms; ETL = 5, matrix = 256 × 192; FOV 
= 230 × 172.5 mm2; slice thickness = 3 mm; total number of slices =
48); (2) a fluid attenuated inversion recovery (FLAIR) scan (TE = 96 ms; 
TR = 8170 ms; TI = 2100 ms;ETL = 13; same matrix and FOV as the dual 
echo; slice thickness = 3 mm, total number of slices = 45); (3) a 
magnetization prepared rapid gradient echo (MPrage) sequence (TE =
2.74 ms; TR = 2500 ms; TI = 900; flip angle = 88◦; matrix = 256 × 208 
× 176; FOV = 256 × 208 × 176 mm3); (4) a series of 12 MT-weighted 3D 
fast low-angle shot (FLASH) sequences (TE = 7.4 ms; TR = 35 ms; flip 
angle = 78; matrix = 128 × 96 × 28; FOV = 230 × 172.5 × 140 mm3), 
optimised for qMT (Cercignani & Alexander, 2006; Cercignani et al., 
2009); (5) three 3D FLASH sequences with three different flip angles 
were collected for mapping the observed T1 of the system (TE = 4.8 ms, 
TR = 15 ms, flip angles = 5, 7, 15◦, respectively, same matrix and FOV as 
the MT sequence) and (6) three 3D FLASH sequences with near-180 flip 
angles were collected for B1mapping (TE = 4.8 ms, TR = 28 ms, flip 
angles = 155◦, 180◦, 205◦, respectively, matrix = 64 × 64 × 40, FOV =
220 × 220 × 160 mm3). The total scan time was approximately 40 min. 
2.4. Lesion contouring and lesion masks 
The volume of white matter lesions was assessed using a semi- 
automated local thresholding contouring software (Jim, Version 7, 
Xinapse Systems, Colchester, UK; www.xinapse.com) on FLAIR scans. 
Dual-echo scans were used as a reference to increase confidence in lesion 
identification. A binary lesion mask was obtained for every subject by 
setting all voxels within a lesion to 1 and the background to zero. The 
resulting lesion masks were coregistered with every patient’s MPRAGE 
using an affine registration in ANTs (Avants et al. 2011). Magnetization 
transfer data were processed using customized software that fits a binary 
spin bath model to the data acquired with variable settings of MT pulse 
offset frequency and flip angle (Cercignani et al., 2009; Giulietti et al., 
2012). Among other model parameters, this process yields maps of the 
pool size ratio (F), computed as F = M0b/M0a, where M0a represents the 
spin density of the liquid pool, and M0b represents the spin density of the 
macromolecular pool. F expresses the relative density of macromole-
cules, it is unitless, and is known to correlate with myelin content (Turati 
et al., 2015). The MPRAGE scan was segmented into white matter, grey 
matter and cerebrospinal fluid (CSF) for every participant. Next, it was 
coregistered to the 15◦ volume acquired as part of sequence 5, used as a 
reference space for the qMT scans. The same transformation was applied 
to the white matter segment. A white matter mask was obtained by 
thresholding the result at 0.8. For all participants with lesions, a NAWM 
mask was obtained by subtracting the lesion mask from the white matter 
mask. The average F was computed within lesions and NAWM for every 
participant. The lesion masks were warped into MNI space and lesion 
probability maps were obtained for each patient group. 
2.5. Identification of temporal lesions 
FLAIR scans and lesion masks of DM1 patients were visually 
inspected by 2 experienced observers to identify the presence of anterior 
temporal lobe lesions. For patients who showed them, separate masks of 
temporal and non-temporal lesions were created, and F values extracted 
for comparison. 
2.6. Volumetric analysis 
As brain atrophy is known to occur in both, MS and DM1, we also 
compared some measures of global and local brain volume. Every par-
ticipants’ MPRAGE was segmented using SPM (Di Paola et al., 2008), 
after lesion filling. The grey matter, white matter and CSF probability 
images in standard space were ‘modulated’, i.e. multiplied by the jaco-
bian of the warping transformation to preserve volumetric information. 
The brain parenchymal fraction (BPF) was computed as the sum of the 
grey and white matter volume divided by the total intracranial volume. 
2.7. Statistical analysis 
Statistical analyses on clinical and imaging data were performed 
using SPSS (SPSS Inc., Chicago, Illinois). The imaging data included in 
the analysis are: lesion load, BPF, mean lesion F, mean NAWM F values. 
Before analysis, data were plotted to check their distribution. Values are 
expressed as mean ± standard deviations (SDs), or as median ± inter-
quartile ranges (IQRs) depending on the normal distribution of the 
values. Student’s t test was used to compare the means of F of lesions 
between patients groups, means of NAWM F and means of BPF between 
the 3 groups. If significant differences in relevant cohort characteristics 
(e.g., age, sex) were present, multiple linear regression analysis was 
Table 1 
Principal clinical and genetic characteristics of DM1 patients.  
Characteristic No (%) of patients 
Age at onset  
Childhood (age range 6–17 years) 8 (29) 
Adulthood (age range, 18–60 years) 20 (71) 
No of CTG triplet repeats on DMPK gene, mean (SD) [range] 469.85 (311.6) 
[54–1200]  
Expansion group  
E1 (50–150) 4 (14%) 
E2(151–500) 13 (46%) 
E3 (501–1000) 9 (32%) 
E4 (>1000) 2 (7%)  
MIRS score  
1 4 (14%) 
2 8 (29%) 
3 12 (43%) 
4 4 (14%) 
5 0 
Abbreviations: DM1: myotonic dystrophy type 1; DMPK: myotonic dystrophy 
protein kinase; MIRS: Muscular Impairment Rating Scale. 
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used. Due to skewness in its distribution, the lesion load data was 
normalized using logarithmic transformation and comparison between 
the means of each group was carried out with Student’s t test. Linear 
regressions were used to examine the relationship between the neuro-
imaging parameters examined and triplet expansion accounting for age. 
3. Results 
3.1. Demographic and clinical characteristics 
The three groups did not differ significantly with regard to sex but 
DM1 patients in our cohort tended to be older (Mean age: 42.1; SD: 12.1 
years) than MS patients (Mean age: 35.8, SD: 7.63 years), and healthy 
controls were younger overall, but a smaller group (Mean 33.8, SD 8.4) 
(X2 1.1p = ns; p = 0.009 respectively). The patients with MS had a 
median expanded disability status scale (EDSS) score of 2.0 (range: 0–4), 
and a mean disease duration of 7.7 years (SD: 4.2). Their mean number 
of years of formal education was 13.2 (SD: 3.5). Table 1 summarizes the 
principal clinical and genetic characteristics of the DM1 patients. A 
larger proportion of patients had adult onset DM1, 20 out of 28 (71%), 
while 8 out of 28 (29%) had childhood disease onset. The mean triplet 
expansion was 469.85, with a range of 54–1200. Each expansion was 
grouped according to the guidelines of the Myotonic Dystrophy con-
sortium (IDMC, 2000). 
3.2. Lesion burden and radiological results 
As we expected, patients with MS in our cohort had more extensive 
white matter disease. Once normalised on the logarithmic scale, an in-
dependent t test demonstrated that the mean lesion volume was higher 
in MS (median 6386, IQR 20100) than DM1 (median 2288.8, IQR 
6995.3) (p = 0.002, CI − 0.717 to − 0.165). The healthy control cohort 
did not show any macroscopic lesions. The BPF was lower in MS than in 
DM1 patients (p = 0.009, CI = 0.009–0.06), and higher in healthy 
controls than in both patient groups (p = 0.0001, CI = 0.034–0.099 for 
MS, and p = 0.02, CI = 0.005–0.06 for DM1). 
Table 2 summarises the principal MRI characteristics of the patient 
groups. 
Examining the lesion substrate of all patients, we found more evi-
dence of myelin disruption within lesions compared to NAWM, with the 
mean F of lesions being lower than the NAWM (p < 0.01, CI 0.06–0.07), 
and lower in MS than in DM1 (p < 0.01, CI 0.01–0.04). 
In addition to examining the lesion volume in each group, we also 
investigated the distribution of lesions in each cohort by creating lesion 
masks and probability maps. Fig. 1 shows the lesion distribution in the 2 
patient groups, highlighting the overall greater lesion load in MS pa-
tients. Although the lesion volume was smaller in DM1 patients, the 
distribution was similar with the following exceptions: DM1 patients did 
not show any lesions in the cerebellum and brainstem; 3 out of 28 DM1 
patients (11%) presented with a pattern of temporal lobe lesions typical 
for DM1 (Fig. 2). Given the small number of DM1 patients with typical 
temporal lesions, no formal statistical comparison was performed. A plot 
of the mean F and its SD for every patient is shown in Fig. 3. The data are 
not conclusive but suggest that F might be higher in temporal lobe 
compared to non-temporal lobe lesions. 
Due to the differences in age and sex distribution between groups, we 
performed further multiple regression analyses with NAWM and lesion 
F, respectively, as the dependent variables, and group, age and sex as 
factors. 
This analysis showed significant differences between F of the NAWM 
in the MS group compared to the DM1 (beta 0.45, p < 0.01) and control 
group (beta 0.42, p < 0.01), while there did not appear to be a signifi-
cant difference between NAWM in DM1 patients and controls (beta 
− 0.003, p = ns). Details are shown in Table 3. 
Within lesions, multiple regression analysis indicated that patients 
with MS had significantly lower F compared to the DM1 cohort (beta 
− 0.28, p < 0.01), when adjusted for age and sex as shown in Table 4. 
There was no association between FLAIR lesion load, lesion F or 
NAWM F and either triplet expansion and age (p value > 0.5 for all 
models explored) in DM1 patients. The triplet expansion number was 
mildly correlated with patient age (p = 0.02, r = 0.43). The F of lesions 
in DM1 was not found to correlate to triplet expansion number (p = ns, r 
= 0.02). Patient age and disease onset did not demonstrate any corre-
lation with lesion load on FLAIR (p = ns, r = 0.27, p = ns r = − 0.14). 
We found a statistically significant difference between lesion load in 
DM1 patients with adulthood and childhood onset on FLAIR once 
transformed to allow normalization of the data. (Adult onset: n = 20 
med 3134.8 IQR 8414.75; Childhood onset: n = 8, med = 1898.2, IQR =
1857.6; p = 0.03. 95% CI 0.03 to 0.68). However, within the childhood 
onset group there were less patients, and the age range of this group was 
18–55, with a younger median age of 32, compared to 45 (range 31–69) 
for the adult onset group which may explain some of this variation. 
Examining for correlation between many of the clinical variables 
with imaging results using Spearman’s and Pearson’s coefficient 
(depending on the normality of the variable) did not demonstrate any 
significant correlation except for age and triplet expansion, which was 
mildly correlated. Given the large number of comparisons, however, this 
result cannot be considered conclusive. 
4. Discussion 
This study demonstrates that the white matter lesion distribution in 
people with DM1 largely overlaps with that typical of relapsing remit-
ting MS, and that such lesions are likely to be characterised by demye-
lination, as measured by a reduction in the magnetization transfer 
parameter F. Conversely, no evidence of demyelination within the 
NAWM was observed in DM1 brains. 
4.1. Lesion distribution 
MS lesions are known to be located primarily in a perivascular dis-
tribution (Tallantyre et al., 2008). Although they can form in virtually 
every area of the central nervous system, their density typically in-
creases with proximity to the ventricles, suggesting a role for CSF- 
mediated factors in the accumulation of damage (Jehna et al., 2015). 
Our results suggest that white matter lesions tend to follow a similar 
anatomical pattern in DM1 patients, at least in the supratentorial 
compartment. Whether this distribution is suggestive of similar mech-
anisms of lesion formation remains to be clarified. Lesion distribution in 
MS has been postulated to be related to lymphocyte trafficking pathways 
and distinct antigen presentation depending on the particular area of the 
central nervous system involved (Gross et al., 2017). It is likely that the 
mechanism is different in DM1, however an inflammatory reaction to 
RNA inclusion bodies may be a hypothesis to consider. Despite the 
similar lesion distributions in the 2 patient cohorts (i.e., DM1 and MS), 
there were also some important differences. First, none of the DM1 pa-
tients showed any lesions in the cerebellum and brainstem, which again 
remarks substantial pathophysiological differences between DM1 and 
Table 2 
MRI measurements from DM1 and MS patients, and healthy controls.  
Characteristics DM1 patients 
(n = 28) 
MS patients 




Lesion Load on FLAIR in 






Lesion F, mean [SD] 0.14 [0.02] 0.12 [0.02] N/A 
NAWM F, mean [SD] 0.21 [0.01] 0.17 [0.02] 0.22 [0.01] 
BPF 0.802 [0.043] 0.767 [0.053] 0.834 [0.040] 
Abbreviations: DM1: myotonic dystrophy type 1; FLAIR: fluid attenuated 
inversion recovery; MS: multiple sclerosis; NAWM: normal appearing white 
matter; BPF = brain parenchymal fraction. 
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MS with respect to macroscopic white matter damage. Interestingly, 
infratentorial lesions are common in MS, and often associated with 
clinical symptoms when in relation with an acute MS relapse. In addi-
tion, 3 DM1 patients (but none of the MS patients) showed the typical 
anterior temporal white matter lesions (Fig. 2). This is consistent with 
previous imaging studies of patients with DM1 demonstrating specificity 
for the anterior temporal region (Miaux et al., 1997; Ogata et al., 1998), 
whose pathological substrate has been characterized by decreased 
myelin sheaths and severely disordered arrangement of axons with 
microscopically heterotopic neurons (Ogata et al., 1998). As only 3 
patients in our sample presented with anterior temporal lobe lesions, it 
was not possible to perform a formal statistical analysis of those patients 
or investigate any correlation with triplet size or a significantly larger 
lesion load compared to other parts of the brain. Nonetheless, these 
anterior temporal lesions showed (in 2 out of 3 cases) higher F values in 
comparison with those distributed to other brain regions. It is difficult to 
provide a definite interpretation of this finding. Post-mortem studies of 
DM1 have recognized different substrates in different areas of the brain, 
such as inclusion bodies in the cerebral cortex and neurofibrillary tan-
gles in the temporal lobes, a finding which may suggest that the varia-
tion of lesion distribution being seen, could occur due to different 
substrate involvement (Ono et al., 1987, 1989). However, it is also 
possible that these differences are explained by intrinsic variations in 
tissue type. A similar finding, differentiating between periventricular 
and deep white matter hyperintensities in an aging cohort was inter-
preted as evidence of altered fluid dynamic and CSF leakage in the 
periventricular area, possibly linked to abnormal glymphatic system 
function (Iordanishvili et al., 2019). Although this is an intriguing hy-
pothesis, given the small number of anterotemporal lesions in this study, 
we refrain from speculating on this subject. Considering the questions 
remaining regarding the mechanisms of disease, in future research, it 
may be important to compare DM1 with other genetically inherited 
neurological disorders, which predominantly affect white matter, 
through imaging and histological studies. CADASIL is an arteriopathy 
which results in white matter disease, predominantly in the anterior 
temporal lobes due to vascular insult (Liem et al., 2008). Mitochondrial 
neurogastrointestinal encephalopathy (MNGIE) is a rare autosomal 
recessive disorder caused by mutations in the thymidine phosphorylase 
gene, which leads to excess levels of thymidine and resultant mito-
chondrial DNA replication abnormalities. A study by Gramegna et al. 
found evidence of microvascular damage leading to diffuse white matter 
involvement in patients with MNGIE on brain MRI, MR spectroscopy 
and histopathology (Gramegna et al., 2018a). Additionally, another 
interesting observation by the same group has highlighted the potential 
role of mitochondrial dysfunction in DM1, illustrating that patients with 
higher levels of CSF lactate on MR spectroscopy also demonstrate 
greater white matter disease (Gramegna et al., 2018b). Comparing these 
disease entities using advanced neuroimaging techniques alongside 
histopathology could shed further light on the disease mechanisms 
involved in DM1. 
4.2. Lesion substrate 
With regards to the quantitative analysis, we demonstrate that, while 
we found no evidence of demyelination in the NAWM of DM1 patients in 
our study, F values within the lesions are significantly reduced, sug-
gesting a reduction in myelin density. It should be reiterated, however, 
that F is computed as a ratio, and therefore a reduction could be caused 
by either, a decrease in the numerator, or an increase in the denomi-
nator. The latter could happen in the presence of oedema (i.e., an in-
crease in free water). Indeed, previous experimental studies have 
demonstrated that inflammation in the absence of demyelination can 
cause similar changes (Stanisz et al., 2004). Therefore this study cannot 
conclude with absolute certainty that demyelination explains all the 
observed changes in F from DM1 brains. The average F values from DM1 
lesions are higher than MS lesions, suggesting a less extensive loss of 
myelin, but they are significantly lower than in the NAWM, and than in 
the white matter of healthy controls. Neuropathological investigations 
in DM1 are extremely limited (Ogata et al., 1998; Mizukami et al., 1999; 
Itoh et al., 2010). Itoh et al. (2010) who examined 11 patients with DM1 
Fig. 1. Lesion distribution. Panel A shows the lesion probability maps for DM1 (top) and MS (bottom). Panel B shows the sum of the probabilities over each section in 
the axial (left) and coronal (right) planes. It can be seen that MS patients have higher probability of lesions at every level except at MNI z coordinates ranging from 
− 40 to − 20. Panel C demonstrates that in correspondence with these coordinates, DM1 patients show extensive lesions in the anterior temporal lobe, while MS 
patients have primarily sub-tentorial lesions, in the brainstem and cerebellum. Abbreviations: DM1: myotonic dystrophy type 1, MS: Multiple sclerosis. 
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reported, in the deep white matter, microscopic evidence of dilated 
perivascular spaces, loss of adjacent axons and myelin, capillary hyali-
nization, and fibrillary gliosis. They argued that the macroscopic lesions 
detectable on MRI scans in the white matter of DM1 patients may be 
considered as instances of état criblé and represent a DM1 specific 
morphological change. Interestingly, they did not report any obvious 
abnormality in the NAWM, consistently with our current results. 
Although MTR has been used previously to investigate brain changes 
occurring in DM1, this is the first study to use qMT. It is important to 
Fig. 2. Axial sections of the fluid-attenuated inversion recovery (FLAIR) scans, showing the anterior temporal lesions observed in 3 patients with myotonic dystrophy 
type 1 (P1, P2, P3). 
Fig. 3. Mean (SD) F value in temporal (blue) and non-temporal (red) lesions, 
for the 3 patients with myotonic dystrophy type 1 who presented with anterior 
temporal lobe lesions. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article.) 
Table 3 
Summary of Multiple Regression analysis for model examining difference in 
variances of NAWM F values in MS compared to DM1 patients and healthy 
controls adjusted for age and sex.  
Variable ϐ P value Confidence interval 
Intercept  0.225   
DM1  0.45  <0.001 0.033 to 0.057 
Control  0.42  <0.001 0.028 to 0.055 
Age  0.00  0.858 0.0 to 0.0 
Sex  − 0.011  0.013 − 0.019 to − 0.002 
Abbreviations: DM1: myotonic dystrophy type 1; MS: multiple sclerosis; NAWM: 
normal appearing white matter. 
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reiterate that this technique provides a more specific quantification of 
myelin than MTR, as the MTR is acquisition-dependent and incorporates 
effects independent of myelin content (Cercignani & Bouyagoub, 2018), 
such as changes in T1 (Henkelman et al., 2001) and changes in extra-
cellular volume fraction (Stanisz et al., 2004). This might explain why a 
previous investigation of NAWM in DM1 using MTR found significant 
differences between DM1 patients and healthy controls (Naka et al., 
2002) while we did not. It is possible that the changes observed by Naka 
et al. (2002) are explained by substrates other than demyelination. An 
additional difficulty in comparing results of studies in this patient cohort 
rests on the small numbers often included, the significant effects of 
anticipation and expansion number on phenotype, the variation in 
group onset and in imaging protocols, some or all of which may help 
explain the difference in results with respect to the NAWM. Our findings 
are consistent with other studies demonstrating reduced F value within 
lesions in MS, in terms of the values of the lesions’ substrate (Sled 2018). 
As qMT is a relatively novel technique, not available on clinical scan-
ners, it is difficult to find studies that have applied it to diseases such as 
CADASIL, which would be very helpful to compare against our current 
findings. 
4.3. Correlation with clinical and genetic data 
Our results did not demonstrate any correlation between triplet 
number and lesion load, F value or MIRS(Muscular impairment rating 
scale) scores. There has been reported variability between triplet size 
depending on the site at which it is sampled, for example, repeats are 
larger in muscle samples than in corresponding blood samples (Thorn-
ton et al., 1994). In clinical practice samples are always taken from the 
blood, however it is possible that CSF samples might more accurately 
reflect increasing lesion load or changes in the central nervous system, 
and this may be something to consider in future studies. Different studies 
have demonstrated varied results with regards to correlation between 
MRI changes, clinical findings, cognition, and triplet expansion (Meola 
and Sansone, 2007; Serra et al., 2015). This disparity again may result 
from the well-known heterogeneity within this patient group due to 
differences in genetic inheritance and expression, clinical phenotypes, 
and notably study designs. It has been shown that modal CTG repeat 
length might not be the best variable to consider for these correlations, 
as it tends to correlate with the age of onset (Cumming et al., 2019). 
Instead, progenitor CTG repeat length is the best predictor of risk 
severity and the best index to correlate with clinical or neuroimaging 
findings (Cumming et al., 2019; Morales et al., 2020). This information 
was not available for this study and we have tried to mitigate the 
problem by accounting for age of particiapants. However, this should be 
regarded as a limitation. 
4.4. Limitations 
This study has other limitations; our sample size is small, which is in 
keeping with DM1 being a relatively rare disease. The DM1 cohort is 
smaller again, once divided into adult and childhood onset. Differences 
of disease onset may demonstrate more significant differences in a larger 
cohort. It is well known that patients with DM1 experience genetic 
anticipation, with earlier symptomatic and more severe disease in 
families who have had successive affected generations (Höweler et al., 
1989). We could not examine whether the prevalence of white matter 
disease is greater in those patients with a more significant family history. 
In addition to this, despite our relatively young cohort of DM1 patients, 
they were significantly older than both the MS cohort and healthy 
controls. With regards to this, it would be useful to examine the effect of 
disease duration and age on the extent of white matter disease, which is 
something that could be considered in future studies. A further point of 
interest might have been to examine whether the participants had 
inherited DM1 from the maternal or paternal line. Martorell et al. sug-
gested that patients with paternal inheritance can exhibit low numbers 
of triplet expansions while those with maternally inherited disease are 
more likely to suffer from clinically significant disease (Martorell et al, 
2001; Martorell et al., 2007). The existence of co-morbidities such as 
ischaemic heart disease, hypertension and smoking, which may be 
present in DM1 as in the general population, may also contribute to 
white matter disease but these variables were not examined in this 
study. They are variables which may be useful to be aware of in future 
studies. Finally, we have not included patients with congenital or late 
DM1 clinical onset . Future studies comparing lesion distribution and 
load in these subgroups of patients is an area which may add further 
weight to the specificity of DM1 lesions to the temporal lobes and the 
nature of white matter changes. 
4.5. Conclusion 
In conclusion, we have shown that the distribution of lesions within 
the white matter is similar in DM1 and MS, suggesting that proximity to 
the ventricles might increase susceptibility to tissue damage regardless 
of the underlying pathological mechanism. In addition, we have 
demonstrated that demyelination occurs within DM1 lesions, but not in 
the NAWM, and that the DM1 typical anterior temporal lesions might be 
different from the periventricular ones. These data support the use of 
quantitative MRI techniques for the characterization of brain changes 
associated with DM1, and the need for sensitive non-invasive imaging 
biomarkers to aid in our monitoring of progression, possible response to 
treatment and advancing our understanding of this disease. 
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